Marc Feldmann
20Patents
7h-index
22Co-inventors
69Inventor score
Filing activity: May 10, 1993 → Apr 14, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5633145A | TNF.alpha. receptor-derived binding protein | Emerging Cross-Sectional Technologies | 27 | Expired |
| US6410588B1 | Use of cannabinoids as anti-inflammatory agents | Human Necessities | 21 | Expired |
| US5863786A | Nucleic acid encoding modified human tnf.alpha. (tumor necrosis factor alpha) receptor | Emerging Cross-Sectional Technologies | 18 | Expired |
| US5958409A | Method for treating multiple sclerosis | Human Necessities | 13 | Expired |
| US7846442B2 | Methods of treating rheumatoid arthritis with an anti-TNF-alpha antibodies and methotrexate | Chemistry; Metallurgy | 13 | Active |
| US7838489B2 | Methods of treating rheumatoid arthritis with p75 TNF-alpha receptor and methotrexate | Chemistry; Metallurgy | 10 | Active |
| US6770279B1 | TNF&agr; antagonists and cyclosporin in therapy of rheumatoid arthritis | Human Necessities | 9 | Expired |
| US7608262B2 | Methods of preventing or treating thrombosis with tumor necrosis factor antagonists | Chemistry; Metallurgy | 4 | Expired |
| US7915009B2 | Activation and inhibition of the immune system | Chemistry; Metallurgy | 3 | Expired |
| US8298537B2 | Concomitant treatment of rheumatoid arthritis with anti-TNF-α antibodies and methotrexate | Chemistry; Metallurgy | 3 | Active |
| US7070783B1 | Small molecular weight TNF receptor multimeric molecule | Emerging Cross-Sectional Technologies | 2 | Expired |
| US7390630B1 | Method of identifying a compound that selectively inhibits cytokine-stimulated T cell induced production of TNF-alpha by monocytes | Physics | 2 | Expired |
| US10500273B2 | Method of treating a localized fibrotic disorder using an IL-33 antagonist | Chemistry; Metallurgy | 1 | Active |
| US11220540B2 | Methods for reducing post-operative cognitive dysfunction (POCD) | Chemistry; Metallurgy | 1 | Active |
| US12325744B2 | Methods for reducing post-operative cognitive dysfunction (POCD) | Chemistry; Metallurgy | 0 | Active |
| US11613570B2 | Method of treating dupuytren's disease using a pre-filled syringe | Human Necessities | 0 | Active |
| US8383120B2 | Concomitant treatment of rheumatoid arthritis with anti-TNF-alpha antibodies and methotrexate | Chemistry; Metallurgy | 0 | Active |
| US12344667B2 | Method of treating early stage Dupuytren's disease | Human Necessities | 0 | Active |
| US7651857B2 | Methods for enhancing antigen presentation | Chemistry; Metallurgy | 0 | Expired |
| US11400154B2 | Method of treating a localized fibrotic disorder using an IL-33 antagonist | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.